| Home > Zentren > Zentrum für Diagnostik > Institut für Klinische Chemie / Zentrallaboratorien > Publikationen > Publikationen 2009
Molekulare Onkologie - Entstehung, Progression, klinische Aspekte
Wagener/Müller, 2009
Bestellschein
Beil FT , Barvencik F, Gebauer M, Beil B, Pogoda P, Rueger JM, Ignatius A, Schinke T, Amling M.
Effects of increased bone formation on fracture healing in mice
J Trauma. Accepted Nov 18 2009
Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger KE, Pantel K, Peter-Katalinic J, Brandt BH.
Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile.
J Proteome Res. 2009 Apr;8(4):2004-14
Minibayeva F, Kolesnikov O, Chasov A, Beckett RP, Lüthje S, Vylegzhanina N, Buck F, Böttger M.
Wound-induced apoplastic peroxidase activities: their roles in the production and detoxification of reactive oxygen species.
Plant Cell Environ. 2009 May;32(5):497-508.
Weber W, Buck F, Meyer A, Hilz H.
Prostate specific antigen: one out of five disulfide bridges determines inactivation by reduction.
Biochem Biophys Res Commun. 2009 Feb 20;379(4):1101-6.
Behrens M, Buck F, Meyerhof W.
Substrate specificity of rat DESC4, a type II transmembrane serine protease.
Protein Pept Lett. 2009;16(1):1-6.
Liew CW, Vockel M, Glassmeier G, Brandner JM, Fernandez-Ballester GJ, Schwarz JR, Schulz S, Buck F, Serrano L, Richter D, Kreienkamp HJ.
Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Lett. 2009 Jan 5;583(1):49-54.
Horst AK, Bickert T, Brewig N, Ludewig P, van Rooijen N, Schumacher
U, et al. CEACAM1+ myeloid cells control angiogenesis in inflammation.
Blood. 2009 Mar 9.
Lukacs, Z.; Keil, A.; Hartung, R.; Mengel, E.; Beck, M.; Santer, R.; Nieves Cobos, P.
Fluorimetry and mass spectrometry for the determination of lysosomal enzyme activities in dried blood - possibilities for neonatal screening
Mol Genet Metab 2009, 98: 66
Nieves Cobos, P.; Keil, A.; Santer, R.; Müller-Felber, W.; Schoser, B.; Mengel, E.; Deschauer, M.; Lukacs, Z.
Selective screening for Pompe disease in patients with persistent CK-elevations or limb muscle dystrophy
Mol Genet Metab 2009, 98: 76
Bodamer, O.A.; Dajnoki, A.; Fekete, G.; Keutzer, J.; Orsini, J.; de Jesus, V.; Chien, N.; Hwu, P.; Lukacs, Z.; Zhang, K.; Muhl, A.
Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry
Mol Genet Metab 2009, 98: 108
Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D,
Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S,
Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert
K, Rothe G, Stockinger H, Tárnok A, Taussig MJ, Thiel A, Thiery J, Ueffing
M, Valet G, Vandekerckhove J, Wagener C, Wagner O, Schmitz G.
Approaching clinical proteomics: current state and future fields of
application in cellular proteomics.
Cytometry A. 2009 Oct;75(10):816-32.
Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D,
Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S,
Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert
K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing
M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O, Schmitz G.
Approaching clinical proteomics: current state and future fields of
application in fluid proteomics.
Clin Chem Lab Med. 2009;47(6):724-44.
Brandt DT, Baarlink C, Kitzing TM, Kremmer E, Ivaska J, Nollau P, Grosse R.
SCAI acts as a suppressor of cancer cell invasion through the
transcriptional control of beta1-integrin.
Nat Cell Biol. 2009 May;11(5):557-68.
Dierck K, Machida K, Mayer BJ, Nollau P.
Profiling the tyrosine phosphorylation state using SH2 domains.
Methods Mol Biol. 2009;527:131-55.
Abd Alla J, Reeck K, Langer A, Streichert T, Quitterer
UCalreticulin enhances B2 bradykinin receptor maturation and heterodimerization <http://www.ncbi.nlm.nih.gov/pubmed/19580784>
Biochem Biophys Res Commun. 2009 Sep 11;387(1):186-90
Andresen H, Bingel U, Streichert T, Schmoldt A, Zoerner AA, Tsikas D,
Just I Severe glycerol intoxication after Menière's disease diagnostic--case report and overview of kinetic data. <http://www.ncbi.nlm.nih.gov/pubmed/19514878>
Clin Toxicol (Phila). 2009 Apr;47(4):312-6
Schinke T, Schilling AF, Baranowsky A, Seitz S, Marshall RP, Linn T, Blaeker M, Huebner AK, Schulz A, Simon R, Gebauer M, Priemel M, Kornak U, Perkovic S, Barvencik F, Beil FT, Del Fattore A, Frattini A, Streichert T, Pueschel K, Villa A, Debatin KM, Rueger JM, Teti A, Zustin J, Sauter G, Amling M
Impaired gastric acidification negatively affects calcium homeostasis and bone mass <http://www.ncbi.nlm.nih.gov/pubmed/19448635>
Nat Med. 2009 Jun;15(6):674-81
Xu E, Dubois MJ, Leung N, Charbonneau A, Turbide C, Avramoglu RK, DeMarte L, Elchebly M, Streichert T, Lévy E, Beauchemin N, Marette A.
Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. <http://www.ncbi.nlm.nih.gov/pubmed/19406938>
Endocrinology. 2009 Aug;150(8):3503-12
Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmén J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H.
Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. <http://www.ncbi.nlm.nih.gov/pubmed/19208797>
Clin Cancer Res. 2009 Mar 1;15(5):1566-74
Schulz-Trieglaff O, Machtejevas E, Reinert K, Schlüter H, Thiemann J, Unger K:Statistical quality assessment and outlier detection for liquid chromatography-mass spectrometry experiments. BioData Min 2009;2:4.
Schlüter H, Apweiler R, Holzhütter HG, Jungblut PR:
Finding one's way in proteomics: a protein species nomenclature.
Chem Cent J 2009;3:11.
Ostad MA, Eggeling S, Tschentscher P, Schwedhelm E, Böger R, Wenzel P, Meinertz T, Munzel T, Warnholtz A.
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Atherosclerosis. 2009 Jul;205(1):227-32.
 |
Publikationen nach Jahren |
